TY  - JOUR
T1  - The safety of newly approved medicines: Do recent market removals mean there is a problem?
AU  - Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ
Y1  - 1999/05/12
N1  - 10.1001/jama.281.18.1728
JO  - JAMA
SP  - 1728
EP  - 1734
VL  - 281
IS  - 18
N2  - The removal of 5 pharmaceuticals from the market in a
12-month period because of unexpected adverse events raised concerns
about the adequacy of the drug review process at the US Food and Drug
Administration (FDA). Specifically, concerns were raised about
improvements in drug review efficiency that significantly reduced FDA
review times. We have reviewed the circumstances of the 5 removals to
determine whether there was any relationship to the increased
efficiencies in the drug review process. When the removed drugs were
analyzed by date of approval, no increase in the number of drugs taken
off the market was seen, demonstrating that reduced review processing
time was not the reason for the cluster of removals. We conclude that
the agency's drug review procedures and postmarketing surveillance
system after a drug has been marketed are currently adequate but must
continually adjust to future challenges.
SN  - 0098-7484
M3  - doi: 10.1001/jama.281.18.1728
UR  - http://dx.doi.org/10.1001/jama.281.18.1728
ER  -